Jae-Jun Shim
Overview
Explore the profile of Jae-Jun Shim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yim H, Seo Y, Kim J, Kim W, Jung Y, Jang J, et al.
Clin Mol Hepatol
. 2025 Jan;
PMID: 39828249
Background/aims: Besifovir (BSV) showed comparable antiviral activity superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy...
2.
Jang T, Liang P, Won Jun D, Jung J, Toyoda H, Wang C, et al.
J Gastroenterol Hepatol
. 2024 Mar;
39(6):1190-1197.
PMID: 38480009
Background And Aim: The benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development of chronic hepatitis B (CHB)-related hepatocellular carcinoma remain controversial. Whether mortality rates differ...
3.
Jang T, Liang P, Won Jun D, Jung J, Toyoda H, Wang C, et al.
Kaohsiung J Med Sci
. 2023 Oct;
40(2):188-197.
PMID: 37885338
Elevated serum gamma-glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)-related hepatocellular carcinoma. However, their role in predicting mortality in patients with CHB treated with nucleotide/nucleoside analogs (NAs)...
4.
Chen R, Coleborn E, Bhavsar C, Wang Y, Alim L, Wilkinson A, et al.
Mol Ther Oncolytics
. 2023 Oct;
31:100725.
PMID: 37781339
Immunotherapies have emerged as promising strategies for cancer treatment. However, existing immunotherapies have poor activity in high-grade serous ovarian cancer (HGSC) due to the immunosuppressive tumor microenvironment and the associated...
5.
Chau A, Yeh M, Tsai P, Huang D, Kim S, Trinh H, et al.
Clin Gastroenterol Hepatol
. 2023 Sep;
22(3):572-580.e5.
PMID: 37734582
Background & Aims: It is unclear if there may be sex differences in response to nucleos(t)ide analogs including virologic response (VR), biochemical response (BR), complete response (CR), and hepatocellular carcinoma...
6.
Lee H, Kim G, Oh C, Shim J, Kim B
J Liver Cancer
. 2023 Jun;
20(2):148-153.
PMID: 37384326
Optimal treatments for patients with advanced hepatocellular carcinoma (HCC) are still limited and their prognosis remains dismal. Yet, there have been rare cases that have shed light on longer survival...
7.
Kwon K, Shim J, Kim G, Kim B, Han H, Ahn H
Korean J Intern Med
. 2023 Apr;
38(3):338-348.
PMID: 37032119
Background/aims: Chronic hepatitis C (CHC) is the second leading cause of liver-related mortality and is more prevalent in the elderly population in Korea. Decisions to initiate treatment and selection of...
8.
Hur M, Park M, Yip T, Chen C, Lee H, Choi W, et al.
Am J Gastroenterol
. 2023 Mar;
118(11):1963-1972.
PMID: 36881437
Introduction: Tenofovir disoproxil fumarate (TDF) is reportedly superior or at least comparable to entecavir (ETV) for the prevention of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B; however, it...
9.
Choi W, Kim G, Park J, Jang S, Jung W, Shim J, et al.
J Korean Med Sci
. 2022 Aug;
37(33):e255.
PMID: 35996932
Background: Angiotensin type II receptor blockers (ARBs) are the most widely used anti-hypertensive drugs. This study aimed to elucidate the likelihood and pattern of ARB-induced liver injury in a hospital-based...
10.